27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
Research from industry analyst GlobalData shows that domestic drug developers in China are leading the way in CAR-T cell therapy trials, with 337 company-sponsored studies underway. 19 August 2021
Shares of China-headquartered Adagene were down 3.9% at $17.10 in early trading, despite the company today announcing that it has entered into a third clinical trial collaboration and supply agreement with US pharma giant Merck & Co 19 August 2021
While people in many parts of the world wait in the hope of receiving their first shot of a COVID-19 vaccine, Americans are to be offered their third dose in an attempt to boost immunity to the virus. 19 August 2021
Amid a shortage of vaccines in India, Hyderabad-based public sector undertaking, Indian Immunologicals Limited (IIL) has produced a drug substance to boost the production of Bharat Biotech's vaccine Covaxin. 19 August 2021
US clinical-stage biotech AzurRx BioPharma saw its shares rocket almost 32% to $0.69 yesterday, after it reported some positive mid-stage trials results for its cystic fibrosis candidate MS1819. 19 August 2021
Partners Boehringer Ingelheim and Eli Lilly have announced that Jardiance (empagliflozin) 10mg has been approved by the US Food and Drug Administration (FDA) to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF). 19 August 2021
Shares of Danish CNS specialist Lundbeck closed down 6.9% at 184.45 kroner yesterday as it posted financials for the first half of 2021. 19 August 2021
Otsuka Pharmaceutical yesterday announced top-line outcomes from a Phase II clinical trial that evaluated the safety and efficacy of brexpiprazole for the treatment of patients with borderline personality disorder (BPD), that did not meet the primary endpoint, change from baseline in the Zanarini Rating Scale for BPD. 19 August 2021
Artificial intelligence-driven pharma company Exscientia has taken another step forward in a major collaboration with New York’s Bristol Myers Squibb. 18 August 2021
Privately-held Irish-American company Shorla Pharma has announced a partnership with Eversana to support the launch and commercialization of its oncology portfolio. 18 August 2021
The China National Medical Products Administration (NMPA) has granted Qarziba (dinutuximab beta) conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 months and above, said the drug’s developers, UK-based EUSA Pharma and China’s BeiGene, whose shares rose 1.8% to $286.64 on the news. 18 August 2021
Boston, USA-based start-up Jnana Therapeutics today announced the closing of a $50 million Series B financing, led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures. 18 August 2021
In the UK, a consortium of public and private companies have been awarded part of a £53 million ($73 million) grant from UK Research and Innovation (UKRI) and the Made Smarter initiative. 18 August 2021
For many years, industry commentators have observed that there could be huge untapped therapeutic potential for psychedelics, should the correct development pathways be found. 18 August 2021
US biotech Qualigen Therapeutic' shares tumbled more than 22% to $1.30 yesterday, after it announced its intention to prioritize its focus to its oncology pipeline that includes QN-247 and RAS-F. 18 August 2021
Swedish company Alligator Bioscience saw its shares gain 16.4% to 6.68 Swedish kronor by early afternoon, when it revealed a research and license agreement with Finnish firm Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. 18 August 2021
The US Food an Drug Administration has approved a new indication for Jemperli (dostarlimab-gxly), a programmed cell death receptor-1 (PD-1) blocking antibody from UK pharma major GlaxoSmithKline. 18 August 2021
Boston, USA-based non-profit The Institute for Clinical and Economic Review (ICER) has released its final report into the cost-effectiveness of a range of atopic dermatitis (AD) therapies. 18 August 2021